Tumour necrosis factor α (TNF-α) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: A possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-α therapy for RA

Cytokine

Volumn 12, Issue 3, 2000, Pages 281-288

  Ohshima, Shiro ^a   Mima, Toru ^c   Sasai, Mitsuko ^a   Nishioka, Katsuhiro ^a   Shimizu, Masatoshi ^c   Murata, Norikazu ^d   Yoshikawa, Hiroo ^a   Nakanishi, Katsuyuki ^a   Suemura, Masaki ^a   McCloskey, Richard V ^e   Kishimoto, Tadamitsu ^b   Saeki, Yukihiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

^d MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^e CENTOCOR INC   (United States)

Author keywords

Apoptosis; Fas; RA; Synovial hyperplasia; TNF

Indexed keywords

FAS ANTIGEN; IMMUNOGLOBULIN M; NEUTRALIZING ANTIBODY; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; APOPTOSIS; ARTICLE; CASE REPORT; CELL DEATH; CELL HYPERPLASIA; CONTROLLED STUDY; ELECTRON MICROSCOPY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; OSTEOARTHRITIS; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

EID: 0033923579     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.1999.0552     Document Type: Article

References (22)

1. Cotter TG, Lennon SV, Glynn JG, Martin SJ. Cell death via apoptosis and its relationship to growth, development and differentiation of both tumor and normal cells. Anticancer Res. 10:1991;1153-1160.
2. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or agonists in rheumatoid arthritis. Arthritis Rheum. 33:1990;305-315.
3. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today. 16:1995;39-43.
4. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976.
5. Firestein GS, Yeo M, Zvaifler NJ. Apoptosis in rheumatoid arthritis synovium. J Clin Invest. 96:1995;1631-1638.
6. Nakajima T, Aono H, Hasunuma T, Yamamoto K, Shirai T, Hirohata K, Nishioka K. Apoptosis and functional Fas antigen in rheumatoid arthritis synoviocytes. Arthritis Rheum. 38:1995;485-491.
7. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum. 36:1993;1681-1690.
8. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
9. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN. Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
10. Saxne T, Palladino MA, Heinegard D, Talal N, Wollheim FA. Detection of tumor necrosis factor α but not tumor necrosis factor α in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31:1988;1041-1045.
11. Wakisaka S, Suzuki N, Takeba Y, Shimoyama Y, Nagafuchi H, Takeno M, Saito N, Yokoe T, Kaneko A, Asai T, Sakane T. Modulation by proinflammatory cytokines Fas/Fas ligand-mediated apoptotic cell death of synovial cells in patients with rheumatooid arthritis (RA). Clin Exp Immunol. 114:1998;119-128.
12. Wellwr M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J Clin Invest. 94:1994;954-964.
13. Beg AA, Baltimore D. An essential role for NF-κB in preventing TNFα-induced cell death. Science. 274:1996;782-784.
14. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNFα-induced apoptosis by NF-κB. Science. 274:1996;787-789.
15. Shu HB, Takeuchi M, Goeddel DV. The tumor necrosis factor receptor 2 signal transducers TRAF2 and c-IAP1 are components of the tumor necrosis factor receptor 1 signaling complex. Proc Natl Acad Sci U S A. 93:1996;13973-13978.
16. You M, Ku PT, Hrdlickova R, Bose HR Jr. ch-IAP1, a member of the inhibitor of apoptosis protein family, is a mediator of the antiapoptotioc activity of the v-Rel oncoprotein. Mol Cell Biol. 17:1997;7328-7341.
17. Rothe M, Sarma V, Dixit VM, Goeddel DY. TRAF2-mediated activation of NF-κB by TNF receptor 2 and CD40. Science. 269:1995;1424-1427.
18. Arnett FCSM, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Naustadt DH, Pinals RS, Shaller JG, Sharp JT, Wilder RL, Hunger GG. The American Rheumatism Association 1987 reviced criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:1988;315-324.
19. Alvaro-Gracia JM, Zvafler NJ, Firestein GS. Cytokines in chronic inflammatory arthritis. V. Mutual antagonism between interferon-gamma and tumor necrosis factor-alpha on HLA-DR expression, proliferation, collagenase production, and granulocyte macrophage colony-stimulating factor production by rheumatoid arthritis synoviocytes. J Clin Invest. 86:1990;1790-1798.
20. Llorente L, Zou W, Levy Y, Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, Morel-Fourrier B, Brouet JC, Alarcon-Segovia D, Galanaud P, Emilie D. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med. 181:1995;839-844.
21. Critchfield JM, Racke MK, Zniga-Pflucker JC, Canella B, Raine CS, Goverman J, Lenardo MJ. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science. 263:1994;1139-1143.
22. Meredith RF, Lobuglio AF, Plott WE, Orr RA, Brezovich IA, Russell CD, Harvey EB, Yester MV, Wagner AJ, Spencer SA, Khazacli MB. Pharmacokinetics, immune response, and biodistribution of Iodine-131-labeled chimeric mouse/human IgG1γ 17-1A monoclonal antibody. J Nucl Med. 32:1991;1162-1168.